Lancet Oncology
IF
41.32
Papers
9,447
Papers 9,125
1 page of 913 pages (9,125 results)
Newest
#1Irene Virgolini (MUI: Innsbruck Medical University)H-Index: 46
Source
#2Martyn Caplin (The Royal Free Hospital)H-Index: 68
Last. Eric P. Krenning (EUR: Erasmus University Rotterdam)H-Index: 120
view all 20 authors...
Summary null null Background null The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide alone in patients with advanced midgut neuroendocrine tumours. Here, we report the prespecified final analysis of overall survival and long-term safety results. null null null Methods null This open-label, randomised, phase 3 trial enrolled patients from 41 sites in ...
Source
#1Nehal J. LakhaniH-Index: 16
#2Laura Quan Man Chow (UW: University of Washington)H-Index: 39
Last. Wells A. Messersmith (UCB: University of Colorado Boulder)H-Index: 60
view all 19 authors...
Summary null null Background null Both innate and adaptive immune responses are important components of anticancer immunity. The CD47–SIRPα interaction could represent an important pathway used by tumour cells to evade immune surveillance. We aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and anticancer activity of evorpacept (also known as ALX148), a high-affinity CD47-blocking protein with an inactive IgG Fc region in patients with solid tumours. null null null Methods null ...
Source
#1Francis Lévi (CNRS: French National Centre for Scientific Research)H-Index: 51
Source
#1Matthias Fischer (University of Cologne)H-Index: 51
#2Lucas MorenoH-Index: 21
Last. Johannes H. Schulte (DKFZ: German Cancer Research Center)H-Index: 53
view all 15 authors...
Background null Several paediatric malignancies, including anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumour (IMT), neuroblastoma, and rhabdomyosarcoma, harbour activation of anaplastic lymphoma kinase (ALK) through different mechanisms. Here, we report the safety, pharmacokinetics, and efficacy of ceritinib in paediatric patients with ALK-positive malignancies. null Methods null This multicentre, open-label, phase 1 trial was done at 23 academic hospitals in ten countri...
Source
#1Kelvin C. de Andrade (NIH: National Institutes of Health)H-Index: 8
#2Payal P. Khincha (NIH: National Institutes of Health)H-Index: 14
Last. Sharon A. Savage (NIH: National Institutes of Health)H-Index: 71
view all 8 authors...
Summary null null Background null Li-Fraumeni syndrome, caused primarily by pathogenic or likely pathogenic germline TP53 variants, is a rare, variably penetrant, cancer predisposition syndrome with very high risks of cancer starting in childhood, including the risk of multiple primary malignancies over an individual's lifespan. We aimed to characterise and quantify cancer incidence, patterns, and genotype–phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 v...
Source
#1David C. Qian (Emory University)H-Index: 4
#2Troy J. Kleber (Emory University)H-Index: 2
Last. Zachary S. Buchwald (Emory University)H-Index: 16
view all 14 authors...
Summary null null Background null The dependence of the adaptive immune system on circadian rhythm is an emerging field of study with potential therapeutic implications. We aimed to determine whether specific time-of-day patterns of immune checkpoint inhibitor infusions might alter melanoma treatment efficacy. null null null Methods null Melanoma Outcomes Following Immunotherapy (MEMOIR) is a longitudinal study of all patients with melanoma who received ipilimumab, nivolumab, or pembrolizumab, o...
Source
#1Laurence Brugières (Institut Gustave Roussy)H-Index: 72
#2Zeinab Afify (UU: University of Utah)H-Index: 7
Last. Eric J. Lowe (Boston Children's Hospital)H-Index: 9
view all 3 authors...
Source
#2Pellegrino MustoH-Index: 81
Last. Mario Boccadoro (UNITO: University of Turin)H-Index: 95
view all 25 authors...
Summary null null Background null Bortezomib-based induction followed by high-dose melphalan (200 mg/m2) and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with lenalidomide alone is the current standard of care for young and fit patients with newly diagnosed multiple myeloma. We aimed to evaluate the efficacy and safety of different carfilzomib-based induction and consolidation approaches with or without transplantation and of maintenance treatment with carfilzomib...
Source
#1Hussein Abdul-Hassan Tawbi (The University of Texas MD Anderson Cancer Center)H-Index: 28
#2Peter A. ForsythH-Index: 56
Last. Kim Margolin (City Of Hope National Medical Center)H-Index: 79
view all 25 authors...
Summary null null Background null Combination nivolumab plus ipilimumab was efficacious in patients with asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low efficacy in patients with symptomatic MBM. Here, we provide final 3-year follow-up data from the trial. null null null Methods null This open-label, multicentre, phase 2 study (CheckMate 204) included adults (aged ≥18 years) with measurable MBM (0·5–3·0 cm in diameter). Asymptomatic patients (cohort A) had an Easter...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.